Elevidys Shipments Restart: Sarepta Shares Rebound in US Market
Elevidys shipments have restarted in the U.S., sparking excitement among investors and patients alike. Sarepta Therapeutics, the company behind this muscular gene therapy, saw its shares jump more than 30% before the bell on Tuesday. This news follows a tough period when shipments paused due to the deaths of two teenage boys earlier this year.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
